Effect of low doses of long-chain n−3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial
| Autor: | Wendy L. Hall, Zoitsa Maniou, Thomas A. B. Sanders, Paul T. Seed, Fiona Lewis, Philip Chowienczyk |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Erythrocytes Ambulatory blood pressure Brachial Artery Docosahexaenoic Acids Medicine (miscellaneous) Placebo Gastroenterology Cardiovascular Physiological Phenomena Double-Blind Method Risk Factors Internal medicine medicine.artery Fatty Acids Omega-3 medicine Humans Oily fish Brachial artery Triglycerides Aged Nutrition and Dietetics business.industry Middle Aged medicine.disease Eicosapentaenoic acid Elasticity United Kingdom Vasodilation medicine.anatomical_structure Endocrinology Blood pressure Eicosapentaenoic Acid Cardiovascular Diseases Dietary Supplements Vascular resistance Arterial stiffness Female Vascular Resistance lipids (amino acids peptides and proteins) Endothelium Vascular business |
| Zdroj: | The American Journal of Clinical Nutrition. 94:973-980 |
| ISSN: | 0002-9165 |
| DOI: | 10.3945/ajcn.111.018036 |
| Popis: | Background: The dietary intake of n23 (omega-3) long-chain PUFAs (LC-PUFAs) from fish may improve endothelial function and arterial stiffness. Objective: The objective was to test the hypothesis that increasing intakes of n23 LC-PUFAs—equivalent to the consumption of 1, 2, or 4 portions of oily fish per week—favorably affects endothelial function and arterial stiffness. Design: A parallel-design, randomized, double-blind study compared daily doses of 0.45, 0.9, and 1.8 g n23 LC-PUFAs (EPA: DHA ratio of 1.51:1) with placebo (refined olive oil). The primary and secondary outcomes were changes in flow-mediated dilatation (FMD) of the brachial artery, arterial stiffness, and blood pressure. Nonsmoking men (n = 142) and women (n = 225) aged 45‐70 y were randomly assigned to treatment for 12 mo; 312 subjects completed the intervention. Results: Compliance with the intervention was corroborated by significant dose-dependent increases in the proportions of EPA and DHA in erythrocyte lipids and a 16.5% reduction in serum triacylglycerol concentrations with 1.8 g n23 LC-PUFAs/d. FMD was lower in men than in women (P , 0.0001) and decreased with age (q = 0.270, P , 0.001) but was not significantly (P = 0.781) related to n23 LC-PUFA intake. The mean changes in FMD (95% CIs) compared with placebo were 0.1% (20.9%, 1.1%), 20.3% (21.3%, 0.6%), and 20.3% (21.3%, 0.7%) on daily intakes of 0.45, 0.9, and 1.8 g n23 LC-PUFAs, respectively. No significant treatment effects were noted for arterial stiffness and central mean or 24-h ambulatory blood pressure. Conclusion: Intakes of n23 LC-PUFAs 1.8 g/d do not improve endothelial function in healthy adults. The trial is registered at controlled-trials.com as ISRCTN66664610. Am J Clin Nutr doi: 10.3945/ajcn.111.018036. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|